Chester County News and Community Website
WASHINGTON, D.C. — On Wednesday, the Food and Drug Administration (FDA) released a draft guidance for industry detailing processes and practices for inspections under its Bioresearch Monitoring (BIMO) program. This …
FDA Issues Draft Guidance on Bioresearch Monitoring Inspections Read More
CONSHOHOCKEN, PA — In an important development for patients with non-alcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced findings from new analyses of the Phase 3 MAESTRO-NASH trial at …
New Data Reinforces Effectiveness of Madrigal’s Rezdiffra in NASH Treatment Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More
JENKINTOWN, PA — SFA Therapeutics, Inc. recently announced the completion of patient enrollment for cohort 2 in its Phase 1b clinical trial of SFA-002, aimed at treating mild-to-moderate chronic plaque …
SFA Therapeutics Completes Key Phase 1b Trial Enrollment for Psoriasis Treatment Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a significant development in its ongoing ABOYA-119 clinical trial. The Safety Review Committee (SRC) has approved the commencement of dosing patients …
Aprea Therapeutics Advances Cancer Treatment Trial to Higher Dose Level Read More
PHILADELPHIA, PA — Imvax, Inc. has announced the completion of enrollment in its Phase 2b clinical trial of IGV-001, a novel treatment for newly diagnosed glioblastoma (ndGBM). The trial, which …
Imvax Completes Enrollment for Phase 2b Trial of Innovative Glioblastoma Treatment Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently completed enrollment for its global Phase 3 TrustTSC trial, which is evaluating the efficacy of oral ganaxolone in treating seizures associated …
Marinus Pharmaceuticals Completes Enrollment for Phase 3 Trial on Tuberous Sclerosis Complex Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a significant milestone in cancer treatment. The company recently dosed the first patient in its Phase 1 clinical trial of …
Carisma Therapeutics Launches First Human Trial for CAR-Monocyte Therapy Read More
BERWYN, PA — Mural Health has been awarded the title of “Most Innovative Start-up” at the 2024 Citeline Awards. Citeline, a leader in business intelligence for pharmaceutical and medtech markets, …
Mural Health Named ‘Most Innovative Start-up’ at 2024 Citeline Awards Read More